Emerging drugs for respiratory syncytial virus infection.
about
Virus-induced exacerbations in asthma and COPDIdentification of nucleolin as a cellular receptor for human respiratory syncytial virusRespiratory viral infections in infants: causes, clinical symptoms, virology, and immunology.Respiratory syncytial virus: a prioritized or neglected target?Consequences of non-intervention for infectious disease in African great apes.Soluble leukocyte-Associated Ig-like Receptor-1 in amniotic fluid is of fetal origin and positively associates with lung compliance.Hendra and nipah infection: pathology, models and potential therapies.Emerging paramyxoviruses: molecular mechanisms and antiviral strategiesLactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection.A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial VirusRespiratory syncytial virus disease: update on treatment and prevention.Identifying targets in the hunt for effective respiratory syncytial virus interventions.Perinatal lamb model of respiratory syncytial virus (RSV) infection.Potential Treatment for the Respiratory Syncytial Virus Infections (HRSV)1H, 13C, and 15N resonance assignment of the central domain of hRSV transcription antitermination factor M2-1.Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F2 Subunit are Critical for its Fusion Activity.
P2860
Q27008731-3EC5E1E5-4D44-4CB1-B301-CF1C8595E88EQ28245563-52F8027D-766F-447A-A1D5-AAA3203B6245Q33591243-CAE0EFCF-74E1-417C-B425-8C32C904EB6AQ33852442-9B151411-67FF-498C-8FEF-80D06F8820F0Q34117137-98627EC7-3988-419B-99BD-5FED00C1E8F8Q35080751-6ECDC0B4-2991-4E18-8A35-E06F0B348113Q35658146-C7B076B5-226C-49CB-A77D-3A615F4DE24CQ35658152-5615D5B4-E6EE-486C-B5FE-201E080A73ABQ36114292-44742ECD-9479-443E-AA71-BDE6E45D685CQ36208181-E80AB36F-1BB7-4395-94A7-9B08BD467C39Q37822453-CB253C60-07BC-4D67-A0E0-C52AE13B6F57Q37997822-851E3673-CFE5-477E-9821-9C10F0A8CCE3Q40266020-AA5732FC-36FB-4267-8B2C-B620BCC6E424Q41100150-EBD08594-96AE-442F-BBF7-65E4067783DCQ43661405-C9F49155-2D9A-499B-8C94-EE8F602D9F46Q54216743-392C877C-A366-4FD8-8086-F337B91DD22D
P2860
Emerging drugs for respiratory syncytial virus infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging drugs for respiratory syncytial virus infection.
@en
Emerging drugs for respiratory syncytial virus infection.
@nl
type
label
Emerging drugs for respiratory syncytial virus infection.
@en
Emerging drugs for respiratory syncytial virus infection.
@nl
prefLabel
Emerging drugs for respiratory syncytial virus infection.
@en
Emerging drugs for respiratory syncytial virus infection.
@nl
P2860
P1476
Emerging drugs for respiratory syncytial virus infection.
@en
P2093
Wieslawa Olszewska
P2860
P304
P356
10.1517/14728210902946399
P407
P577
2009-06-01T00:00:00Z